Sygnis Bioscience Gmbh & Co Kg

Biogen Idec, Inc.

Armin Schneider

Martin Maurer

Wolf-Ruediger Schaebitz

Carola Krueger

Clemens Sommer

Stefan Schwab

Rainer Kollmar

Daniela Weber

Nikolaus Gassler

Moritz Rossner

Rico Laage

Rohini Kuner

Dieter Newrzella

Markus Schwaninger

Stephanie Jomana Naim

Birgitta Kammandel

Annette Trutzel

Gisela Eisenhardt

Bernhard Götz

Achim Fischer

Bettina Klaussner

Alfred Bach

Wolfgang Kuschinsky

Tanjew Dittgen

Claudia Pitzer

Carola Krüger

Winfried Koch

Gerhard Vogt

Anja Moraru

C Linda Burkly

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Methods of treating neurological conditions with hematopoeitic growth factors

The present invention relates to a method of treating neurological conditions in a mammal by administering a hematopoietic growth factor such as granulocyte-colony stimulating factor (GCSF) and granulocyte-macrophage colony stimulating factor (GMCSF). The invention also provides methods of screening for compounds that bind to a GCSF or GMCSF receptor found on the surface of a neuronal cell; and which provides a neuroprotective, neuroproliferative and/or a STAT gene activation activity.

Methods of treating neurological conditions with hematopoietic growth factors

The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases.

Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders

The present invention relates to a gene and the coded protein thereof that is involved in the development of sequelae of local ischaemia. The new protein is a serine threonine protein kinase and provides a new therapeutic approach to the prophylaxis and therapy of apoplexy.

Nucleic acid molecule encoding a neuronal serine-threonine protein kinase

Growing community of inventors

Heidelberg, Germany

Armin Schneider